Sakamako Mai Kyau ga Maganin CD7 CAR-T a Maganin Cutar Lymphoma ta T-Cell da ta Daɗe/Tana Ragewa a ASH 2024

A taron shekara-shekara na 66 na Ƙungiyar Nazarin Jini ta Amurka (ASH) ta 2024, wanda aka gudanar daga 7 zuwa 10 ga Disamba a San Diego, Farfesa Lu Peihua na Asibitin Lu Daopei ya gabatar da gwajin asibiti na Mataki na I na maganin T-cell na Chimeric Antigen Receptor T-cell (CAR-T) da aka yi niyya ga CD7 don maganin sake dawowa/rage tasirinsa. Lymphoma na T-Cell (R/R PTCL). Wannan babban ci gaba ne a fannin maganin cututtukan ƙwayoyin T, inda zaɓuɓɓukan magani da ake da su ba su da yawa kuma gabaɗaya ba su da tasiri sosai.

An san R/R PTCL da rashin kyawun hasashenta, musamman ga marasa lafiya waɗanda suka yi jiyya da dama, ciki har da dashen ƙwayoyin halitta na allogeneic hematopoietic (allo-HSCT). Duk da haka, maganin CD7 CAR-T, musamman maganin ƙwayoyin halitta na NS7CAR-T da ƙungiyar Farfesa Lu ta ƙirƙira, ya nuna sakamako mai ƙarfafa gwiwa wajen kula da marasa lafiya da ke da R/R PTCL mai CD7-positive. A cikin wannan gwajin, jimillar marasa lafiya biyar, masu shekaru 39 zuwa 60, waɗanda ke da matakai na ci gaba na R/R PTCL an yi musu rajista tsakanin Afrilu 2021 da Nuwamba 2023. Waɗannan marasa lafiya sun yi matsakaicin layuka shida na magani a baya, ciki har da shari'a ɗaya da ke da tarihin dashen ƙwayoyin halitta na autologous.

Sakamakon ya kasance mai kyau: a cikin matsakaicin lokacin bin diddigin cutar na kwanaki 234, kashi 60% na marasa lafiya sun sami cikakkiyar gafara (CR), kuma wani majiyyaci ya sami sassaucin ra'ayi (PR). Abu mafi mahimmanci, maganin ya nuna babban matakin yaduwar ƙwayoyin CAR-T da juriya a cikin marasa lafiya, tare da matsakaicin matakin kololuwar ƙwayoyin CAR-T ya kai kashi 93.5% na inganci. Abin lura, babu wani mummunan sakamako kamar gubar jijiyoyi, kuma cutar sakin cytokine (CRS) ta kasance mai sauƙi, tare da majiyyaci ɗaya kawai yana fuskantar CRS na aji na II. An iya sarrafa bayanin lafiyar, ba tare da an lura da mummunan guba ba.

Binciken Farfesa Lu ya nuna yuwuwar maganin CD7 CAR-T a matsayin wani abu mai canza yanayin magance cututtukan T-cell, musamman ga marasa lafiya waɗanda ba su da zaɓuɓɓukan magani kaɗan ko babu sauran su. Baya ga sakamako mai kyau a cikin PTCL, ƙungiyar Farfesa Lu ta riga ta sami babban tasiri wajen magance cutar T-cell acute lymphoblastic leukemia (T-ALL) da T-cell lymphoblastic lymphoma (T-LBL), tare da kusan kashi 95% na cikakken adadin yafewa a cikin rukunin marasa lafiya 60. Ganin waɗannan sakamakon, ƙungiyar yanzu tana faɗaɗa bincikenta zuwa wasu cututtukan hematological kamar cutar myeloid leukemia (AML), tare da bayanai na farko da ke nuna cewa kashi 70% na cikakken adadin yafewa ga marasa lafiya da ke da CD7 AML.

Duk da waɗannan sakamako masu kyau, Farfesa Lu ya jaddada mahimmancin haɗa maganin CD7 CAR-T tare da allo-HSCT don inganta sakamako na dogon lokaci. Bambancin cututtukan ƙwayoyin T yana buƙatar dabarun magani mai zurfi don ƙara damar samun gafara mai ɗorewa da yuwuwar warkewa. Ƙungiyar ta ci gaba da inganta hanyarsu da faɗaɗa alamun magani don maganin CD7 CAR-T.

Aikin Farfesa Lu na farko, wanda ya riga ya yi wa marasa lafiya sama da 300 maganin CD7 CAR-T, yana wakiltar babban ci gaba a maganin cutar kansar ƙwayoyin T. A ci gaba da wannan aiki, ƙungiyar ta himmatu wajen ƙara gwaje-gwajen asibiti da kuma inganta dabarun maganin ƙwayoyin CAR-T, tare da tabbatar da cewa ƙarin marasa lafiya za su amfana daga wannan hanyar mai ban mamaki.

Wannan gwajin mataki na farko mai ban sha'awa a ASH 2024 ya nuna yuwuwar maganin CD7 CAR-T a matsayin sabon yanki a fannin ilimin cututtukan jini, yana ba da bege ga marasa lafiya da ke fama da cututtuka da ba a iya magance su a baya ba.